Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (Nasdaq: CNTX) is a Philadelphia-based biopharmaceutical company dedicated to advancing innovative medicines for solid tumors. The company's core mission is to develop novel therapies for hormone-responsive cancers, with a particular focus on female cancers such as breast, ovarian, and endometrial cancer.
Context Therapeutics’ leading clinical candidate is CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target and engage T-cells in attacking CLDN6-positive tumors. Preclinical studies have shown promising results, with CTIM-76 demonstrating a capability to induce complete tumor regressions across multiple dose levels. The company plans to enroll the first patient in a Phase 1 clinical trial in mid-2024.
In addition to CTIM-76, Context Therapeutics is working on other promising programs, including Apristor (onapristone XR), an investigational drug targeting progesterone receptor-positive (PR+) breast cancer. Up to 70% of breast cancers express progesterone receptors, making Apristor a potential treatment option for a significant number of patients.
In recent news, Context Therapeutics announced encouraging financial results for the first quarter of 2024, including gross proceeds of approximately $100 million from a private placement. These funds are expected to support the company's operations and research endeavors well into 2028. The U.S. Food and Drug Administration (FDA) has also recently cleared Context's Investigational New Drug (IND) application for CTIM-76, a crucial step toward initiating clinical trials.
Context Therapeutics has a strong pipeline and strategic partnerships, including collaborations with Integral Molecular, which supports the development of therapies targeting difficult protein targets. The company’s robust financial guidance and innovative approach position it for significant growth in the biopharmaceutical sector.
Context Therapeutics (Nasdaq: CNTX) announced an updated cash guidance extending its runway into Q1 2024. The company will focus on advancing the ONA-XR ELONA Phase 1b/2 clinical trial while deferring noncritical R&D and reducing overhead costs. The trial evaluates ONA-XR in combination with Menarini’s elacestrant for treating metastatic breast cancer. Additionally, Context plans to nominate a CLDN6xCD3 bispecific antibody development candidate and submit an IND in Q1 2024. Preliminary data from ongoing trials is expected in late 2022.
Context Therapeutics Inc. (Nasdaq: CNTX), focused on women's oncology, announces CEO Martin Lehr's participation in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat will be available on demand starting September 12 at 7 a.m. ET. The company will also hold in-person meetings at the conference in New York City. Context is advancing treatments for breast and gynecological cancers, with ongoing Phase 2 trials for its drug candidate, Onapristone extended release (ONA-XR).
Context Therapeutics (CNTX) announced a collaboration with Menarini Group to assess ONA-XR alongside elacestrant in metastatic breast cancer. The company reported a net loss of $4.0 million for Q2 2022, an improvement from $5.0 million in Q2 2021. Cash reserves stood at $42.9 million as of June 30, 2022, projected to sustain operations until Q4 2023. Notable pipeline advancements include ongoing Phase 2 trials with preliminary data anticipated in Q4 2022 and plans to initiate the ELONA trial by year-end.
Context Therapeutics (Nasdaq: CNTX) announced a collaboration with Menarini Group to support a Phase 1b/2 clinical trial of ONA-XR, an oral progesterone receptor antagonist, combined with elacestrant, a selective estrogen receptor degrader. Targeting ER+, PR+, HER2- metastatic breast cancer patients previously treated with a CDK4/6 inhibitor, this trial aims to explore enhanced tumor control through dual ER and PR blockade. Elacestrant showed a 30% reduction in progression risk compared to standard therapies. The trial is set to initiate in Q4 2022.
Context Therapeutics Inc. (Nasdaq: CNTX) reported its Q1 2022 financial results, revealing a net loss of $3.4 million compared to $0.9 million in Q1 2021. Cash and cash equivalents declined to $45.7 million from $49.7 million at year-end 2021. The company presented promising data from its ONA-XR clinical trial at the AACR Annual Meeting and has ongoing Phase 2 trials for breast, ovarian, and endometrial cancers. Preliminary data from these trials is expected later in 2022, alongside the selection of a candidate for the CLDN6xCD3 program.
Context Therapeutics Inc. (Nasdaq: CNTX) announced promising results from its Phase 2 trial of ONA-XR, a progesterone receptor antagonist, in treating advanced granulosa cell tumors. The results will be presented at the ASCO Annual Meeting scheduled for June 3-7, 2022. The study has progressed to evaluate ONA-XR in combination with the antiestrogen anastrozole. CEO Martin Lehr expressed optimism about ONA-XR's potential in targeting this rare ovarian cancer type. The abstract highlights significant activity of ONA-XR, marking a pivotal step in Context's clinical program for women's oncology therapies.
Context Therapeutics announced promising preclinical results for its lead candidate, ONA-XR, a progesterone receptor antagonist, at the AACR Annual Meeting 2022. The data showcases ONA-XR's potential in combination with standard therapies for hormone-positive tumors, demonstrating significant tumor regression in various preclinical models. Additionally, the company is progressing with its CLDN6xCD3 bispecific antibody program, aiming for candidate selection for IND-enabling studies by year-end. Preliminary data from ongoing Phase 2 trials is expected later this year.
Context Therapeutics announced that CEO Martin Lehr will participate in two virtual investor conferences in April 2022. The events include Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference on April 14 at 8:30 a.m. ET and the 21st Annual Needham Virtual Healthcare Conference on the same day at 2:15 p.m. ET. Context is focused on developing small molecule and immunotherapy treatments for breast and gynecological cancers, with its lead candidate ONA-XR undergoing multiple clinical trials.
Context Therapeutics (Nasdaq: CNTX) announced financial results for the year ending December 31, 2021, reporting a net loss of $10.5M compared to a net income of $6.6M in 2020. The company raised $28.75M from its IPO and $31.25M in a private placement, strengthening its cash position to $49.7M, sufficient to fund operations into 2024. Context highlighted positive preclinical data for its ONA-XR candidate and plans for upcoming Phase 2 clinical trial data. The company expects preliminary results from several trials in mid-2022 and aims to introduce a new bispecific antibody candidate for ovarian and endometrial cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) has announced that five abstracts will be presented at the AACR Annual Meeting 2022 from April 8-13 in New Orleans, LA. The company is focusing on its lead product candidate, onapristone extended release (ONA-XR), aimed at treating various hormone-driven female cancers. A webinar is scheduled for April 13, 2022, at 11 a.m. ET, where management will discuss these presentations and provide updates on ONA-XR's clinical program. Context has a robust clinical pipeline, including multiple ongoing trials for its promising therapies.
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
What does Context Therapeutics Inc. do?
What is CTIM-76?
What types of cancer is Context Therapeutics targeting with their therapies?
What recent milestones has Context Therapeutics achieved?
When does Context Therapeutics plan to start the Phase 1 trial for CTIM-76?
What are the financial prospects for Context Therapeutics?
Who are some of Context Therapeutics' strategic partners?
What regulatory approvals has Context Therapeutics received recently?
Where is Context Therapeutics headquartered?
What is Apristor?
